Cytori Therapeutics is a cell therapeutic/device company focusing on autologous adipose-derived stem and regenerative cells (ADRCs) driven cell therapies to treat cardiovascular disease and soft tissue disorders. The company developed its proprietary and automated Celution System device for the extraction and preparation of clinical grade ADRCs as a point-of-care treatment. Based on the scientific and clinical data, ADRCs-based treatment potentially could be used across multiple ischemic conditions.
Cytori is conducting a Phase II (ATHENA) study with a second trial (ATHENA II) to come in no-option chronic myocardial ischemia (CMI) patients. Top-line data potentially become available in 2H14 and 2015, respectively. Positive results would be major catalysts for CYTX share value appreciation. In addition, Biomedical Advanced Research and Development Authority (BARDA) have a contract with the company for the development of Celution System as a treatment for thermal burns combined with radiation injury potentially to be used following a mass-casualty event. Advancement into the 2nd phase of the BARDA development with potentially $56MM of funding could occur in 2014 – a substantial near-term catalyst for the stock.